{"id":"piperacillin-sodium-and-sulbactam-sodium","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Phlebitis at injection site"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL1200820","moleculeType":"Small molecule","molecularWeight":"539.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Piperacillin is a broad-spectrum β-lactam antibiotic that disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis and death. Sulbactam is a β-lactamase inhibitor that protects piperacillin from enzymatic degradation by resistant bacteria, extending the spectrum of activity against β-lactamase-producing organisms. Together, this combination provides enhanced coverage against gram-positive, gram-negative, and anaerobic bacteria.","oneSentence":"Piperacillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, while sulbactam inhibits bacterial β-lactamases to prevent antibiotic degradation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:32.424Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections caused by susceptible organisms including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and respiratory tract infections"},{"name":"Polymicrobial infections including those with β-lactamase-producing organisms"}]},"trialDetails":[{"nctId":"NCT07318584","phase":"PHASE2","title":"Cefotetan Therapy for Escherichia Coli Infections","status":"NOT_YET_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-03","conditions":"E Coli Infection, ESBL Producing E.Coli","enrollment":84},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":"Community-acquired Pneumonia","enrollment":330},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT04724044","phase":"PHASE3","title":"Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2021-01-25","conditions":"Community-acquired Pneumonia, Sepsis, Inflammatory Response","enrollment":278},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT03776409","phase":"","title":"Safety and Efficacy of Vancomycin Plus Beta-lactams","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2018-12-12","conditions":"Critical Illness","enrollment":700},{"nctId":"NCT01760109","phase":"PHASE4","title":"Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection","status":"COMPLETED","sponsor":"Xiangbei Welman Pharmaceutical Co., Ltd","startDate":"2011-07","conditions":"Respiratory Tract Infections, Urinary Tract Infections","enrollment":2000},{"nctId":"NCT01897831","phase":"PHASE4","title":"Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection","status":"UNKNOWN","sponsor":"Xiangbei Welman Pharmaceutical Co., Ltd","startDate":"2011-08","conditions":"Respiratory Tract Infections, Urinary Tract Infections","enrollment":2000},{"nctId":"NCT00044746","phase":"PHASE4","title":"Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-10","conditions":"Diabetes Mellitus, Diabetic Foot","enrollment":314}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["xin te mie","te mie jun","xin ke jun"],"phase":"marketed","status":"active","brandName":"Piperacillin Sodium and Sulbactam Sodium","genericName":"Piperacillin Sodium and Sulbactam Sodium","companyName":"Xiangbei Welman Pharmaceutical Co., Ltd","companyId":"xiangbei-welman-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piperacillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, while sulbactam inhibits bacterial β-lactamases to prevent antibiotic degradation. Used for Bacterial infections caused by susceptible organisms including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and respiratory tract infections, Polymicrobial infections and infections caused by β-lactamase-producing bacteria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}